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Synthesis of Broad-Specificity Activity-Based Probes for Exo-β-
Mannosidases
Nicholas G. S. McGregora, Chi-Lin Kuob, Thomas J. M. Beenakker,b Chun-Sing Wongb, Wendy A. 
Offena, Zachary Armstronga, Bogdan I. Floreab, Jeroen D. C. Codéeb, Herman S. Overkleeftb, 
Johannes M. F. G. Aertsc,*, Gideon J. Daviesa,*
Exo--mannosidases are a broad class of stereochemically retaining 
hydrolases that are essential for the breakdown of complex 
carbohydrate substrates found in all kingdoms of life. Yet the 
detection of exo--mannosidases in complex biological samples 
remains challenging, necessitating the development of new 
methodologies. Cyclophellitol and its analogues selectively label 
the catalytic nucleophiles of retaining glycoside hydrolases, making 
them valuable tool compounds. Furthermore, cyclophellitol can be 
readily redesigned to enable the incorporation of a detection tag, 
generating activity-based probes (ABPs) that can be used to detect 
and identify specific glycosidases in complex biological samples. 
Towards the development of ABPs for exo--mannosidases, we 
present a concise synthesis of β-manno-configured cyclophellitol, 
cyclophellitol aziridine, and N-alkyl cyclophellitol aziridines. We 
show that these probes covalently label exo--mannosidases from 
GH families 2, 5, and 164. Structural studies of the resulting 
complexes support a canonical mechanism-based mode of action in 
which the active site nucleophile attacks the pseudo-anomeric 
centre to form a stable ester linkage, mimicking the glycosyl 
enzyme intermediate. Furthermore, we demonstrate activity-
based protein profiling using an N-alkyl aziridine derivative by 
specifically labelling MANBA in mouse kidney tissue. Together, 
these results show that synthetic manno-configured cyclophellitol 
analogues hold promise for detecting exo--mannosidases in 
biological and biomedical research.
Introduction
Exo--mannosidases, hydrolysing non-reducing terminal  -
D-mannopyranosidic linkages, are widely distributed 
carbohydrate-degrading enzymes.1 In the human gut, exo--
mannosidases of families GH2, GH5, and GH164 are essential 
for the fermentation of β-mannans, such as carob or guar 
endosperm (Ceratonia siliqua) galactomannan, common food 
additives.2–5 In mammals, the lysosomal glycoside hydrolase 
family 2 (GH26) retaining exo--mannosidase, MANBA (EC 
3.2.1.25), is responsible for the cleavage of the core Man--1,4-
GlcNAc linkage during lysosomal turnover of N-glycoproteins.7 
Deficiency of this enzyme activity, caused by mutations in 
MANBA8,9, results in -mannosidosis, a rare lysosomal storage 
disorder that can be diagnosed on the basis of elevated Man-β-
1,4-GlcNAc in urine or diminished hydrolysis of 4-
methylumbelliferyl (4-MU) β-D-mannopyranoside in plasma.10–
12 More recently, MANBA deficiency has been identified as a key 
risk factor for chronic kidney disease, which affects roughly 1 in 
10 adults.13–15 
All of these exo--mannosidases process their substrate 
using a stereochemically retaining double displacement 
mechanism that is characterised by the formation of a covalent 
glycosyl enzyme intermediate (GEI, Figure 1A). This two-step 
mechanism, first outlined by Koshland16, can be exploited in the 
development of activity-based probes (ABPs). The natural 
product cyclophellitol, with endocyclic epoxide functionality in 
place of the acetal group found in a typical glycoside, is a potent 
irreversible inhibitor of retaining -glucosidases.17,18 It has been 
demonstrated that altering the characteristic cyclitol ring to emulate 
differently configured monosaccharides yields irreversible inhibitors 
with selectivity towards various retaining exo-glycosidases.19–24 
Moreover, it has been shown that substituting the epoxide in 
cyclophellitol and its configurational isosteres for an N-tagged (e.g. 
fluorophore, biotin) aziridine yields effective ABPs for the discovery 
and visualisation of retaining glycosidases within complex biological 
samples.19,25–28 a.York Structural Biology Laboratory, Department of Chemistry, The University of 
York, York YO10 5DD, UK.
b.Department of Bio-Organic Chemistry, Leiden Institute of Chemistry, Leiden 
University, P. O. Box 9502, 2300 RA Leiden, The Netherlands.
c. Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden 
University, P. O. Box 9502, 2300 RA Leiden, The Netherlands.
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† Electronic Supplementary Information (ESI) available. See 
DOI: 10.1039/x0xx00000x
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Figure 1. A) Conformational reaction itinerary employed by GH2 -mannosidases in the glycosylation half-reaction. MC: Michaelis complex, 
TS: Transition state; GEI: Glycosyl-enzyme intermediate B) Expected reactive binding conformation of compound 1. C) Synthesis of the target 
molecules used in this study. a) mCPBA, DCE, reflux (8: 38%, 9: 26%); b) Pd/C, H2, 1,4-dioxane/tBuOH (9:1), rt., 40%; c) Cl3CCN, DBU, DCM, 
0°C to rt, 30 min, 73%; d) I2, NaHCO3, THF/H2O (4:1), 60°C, 80%; e) i. 1,4-dioxane/H2O/AcOH (1:1:8), rt., 16 h, 75%; ii. NaHCO3, MeOH, rt, 16 
h, 58%; f) Li, NH3 (liq), -60°C, 30 min, quant.; g) 1-azido-8-iodooctane29, K2CO3, DMF, 80°C, overnight, 64%; h) Cy5 alkyne, BODIPY-FL-alkyne30, 
or Biotin alkyne31, CuSO4, sodium ascorbate, H2O/DMF, rt., overnight (4: 17%, 5: 36%, 6: 32%).
The inhibition of exo--mannosidases using cyclophellitol 
derivatives presents a unique challenge. GH2 exo--mannosidases 
process their substrate through a 1S5-B2,5‡-OS2 mechanistic 
conformational itinerary (Figure 1A).32 Due to the strain of the three-
membered ring, cyclophellitols strongly favour 4H3 or 3H4 half-chair 
conformations similar to mannoimidazole, a non-covalent transition 
state mimic.1,33 This matches the substrate conformation of the -
glucosidase transition-state, but presents a significant energy barrier 
to reaching the exo--mannosidase 1S5 pre-catalytic or B2,5 
transition state conformations (Figure 1B).33,34 Thus, cyclophellitol-
derived ABPs may not be able to efficiently label exo--
mannosidases. Furthermore, such a probe might not show 
selectivity towards exo--mannosidases over exo--
glucosidases for the same reason. However, we were 
encouraged by recent work showing that golgi α-mannosidase 
II, using a OS2-B2,5‡-1S5 conformational itinerary, could be 
efficiently probed using an alkylaziridine warhead.23
Results and Discussion
Synthesis of manno-configured cyclophellitols
To determine whether conformational mismatch precludes exo-
-mannosidase inhibition and labelling, we first established an 
efficient synthesis, rooted in the concise Madsen synthesis of 
cyclophellitol.23,35 As for the manno-epi-cyclophellitols, the synthesis 
was initiated from D-ribose instead of D-xylose to obtain the 
necessary stereochemistry (see Figure 1C for synthetic approach).23 
To generate compound 1, key cyclohexene 7 (generated from 
appropriately protected D-ribose in 5 steps) was epoxidized with 
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mCPBA, furnishing partially protected -D-manno-cyclophellitol 
alongside the epimeric epoxide 8. Purification by silica gel 
chromatography yielded pure 9, which was subsequently 
deprotected by palladium-catalysed hydrogenolysis in a 9:1 mixture 
of 1,4-dioxane and tBuOH to provide -D-manno-cyclophellitol 1 in 
40% yield after compound crystallisation. 
To prepare aziridine 2, the intramolecular iodocyclization route 
was chosen over the epoxide opening (with sodium azide) and 
closing (under reducing conditions), to take advantage of the 
stereochemistry of the primary hydroxyl group directing to the beta 
face. Starting cyclohexene 7 was thus treated with 
trichloroacetonitrile to furnish the trichloroacetimidate 10 in 73% 
yield, which was subjected to iodocyclisation to give 11 in 80% yield. 
Acid-mediated hydrolysis of the resulting iminal and base-induced 
intramolecular displacement of the iodine with the liberated primary 
amine gave the partially benzylated aziridine 12. This was reduced 
under Birch conditions to give -D-manno-cyclophellitol aziridine 2 in 
quantitative yield.
Treatment of 2 with 1-azido-8-iodooctane29 and potassium 
carbonate in DMF yielded the N-alkyl aziridine 3 in 64% yield. The 
introduced azide handle was further reacted with Cy5+ alkyne, 
BODIPY-FL-alkyne30 or biotin-alkyne31 under copper(I)-catalysed 
azide-alkyne [2+3] cycloaddition ‘click’ conditions to afford final ABPs 
4, 5, and 6, respectively, in 17 to 36% yield (see supplemental 
information for experimental details on the synthesis and analytical 
details for the intermediates and final products).
Manno-configured cyclophellitols are covalent inhibitors of exo--
mannosidases
Having candidate inhibitors 1-3 and activity-based probes 4-6 we 
initially tested 1, 2, and 3 against a diverse collection of well-
characterised bacterial exo--mannosidases, including 
BtMan2A4, CmMan5A2, and BsGH1645. Where covalent 
inhibition was observed, it was extremely slow. Activity and 
intact MS measurements collected following 25 hours 
incubation of each enzyme with 1 mM of each inhibitor under 
optimal conditions showed distinct patterns of reactivity for 
each enzyme (supplemental figure 1, supplemental table 1). 
BsGH164 did not react with N-octylazido aziridine 3, but was 
labelled by both epoxide 1 (76% inhibition) and aziridine 2 (30% 
inhibition). CmMan5A showed 20% inhibition with both 1 and 
2, and stronger 85% inhibition with 3, indicating that binding is 
enhanced by the presence of the alkyl group. No significant 
inhibition of BtMan2A could be detected following incubation 
with 1 or 2, but the enzyme was 85% inhibited by 3, again 
indicating performance enhancement attributable to the N-
octylazido linker. Assuming a second-order reaction model 
between the enzyme and inhibitor, these measurements imply 
extremely low kinact/KI values for the interaction ranging from 
<0.004-0.034 M-1s-1.
To investigate the structural basis of the observed binding, 
we prepared covalent crystallographic complexes between 
each enzyme and its most reactive ligand. CmMan5A bound to 
compound 3 gave the highest resolution structure at 1.3 Å. 
Supporting our hypothesized mechanism of reactivity, 
compound 3 was covalently linked to E330, the known catalytic 
nucleophile, through its pseudoanomeric carbon (Figure 2A). 
The ring was found in an OS2-like conformation, providing the 
first direct evidence that the GEI conformation for GH5 β-
mannosidases matches that of GH2 β-mannosidases36 and 
GH26 β-mannanases37. The amine group from the opened 
aziridine is found interacting with both the general acid, E215, 
and an apparent buffer acetate that also interacts with the axial 
O3. C7 (taking the place of endocyclic oxygen) forms a CH/π 
interaction (3.4 Å) with W285 while the alkyl chain extends out 
of the catalytic pocket, forming hydrophobic packing 
interactions with W285, W135, and a hydrophobic groove 
between N288 and W289. We speculate that these interactions 
contribute to the observed tighter binding of compound 3 over 
compound 2. Indeed, the first four carbons of the alkyl linker 
display well-localised electron density (B factors of 16-25 Å2), 
indicating rigid binding and suggesting that a shorter linker may 
hinder binding into the active site pocket. 
In contrast, the structure of BtMan2A labelled with 3, solved at 
1.85 Å resolution, showed the ligand bound to the catalytic 
nucleophile in a “relaxed” 4C1-like conformation (supplemental 
figure 2A). The electron density for several aromatic residues lining 
the entrance to the active site pocket, notably W470, W533, and 
Y537 were extremely diffuse, hindering modelling and suggesting a 
high degree of mobility in the complex. The alkyl linker extends into 
a channel lined with these diffuse aromatic residues, possibly giving 
rise to similar, albeit more dynamic, hydrophobic interactions to 
those observed in the CmMan5A active site. Comparisons of the 
labelled enzyme structure to the previously determined structures of 
complexes with 2,4-dinitrophenyl 2-deoxy-2-fluoro-β-D-mannoside 
(2FMan, non-covalent/pre-catalytic) and noeuromycin36, show that 
the ligand has migrated significantly away from the expected 
position of the GEI (supplemental figure 3). Reorientation of the 
catalytic nucleophile breaks the hydrogen bond with O2, allowing 
relaxation of the ring conformation. This makes space for a water 
molecule to interact with R393. Such reorientation is accompanied 
by the displacement of W533 and Y537. Due to the interaction of 
these aromatic rings with the alkyl linker, we hypothesized that 
hydrophobic interactions related to the presence of the octyl linker 
drive this active site rearrangement. To test this hypothesis, we 
performed an extensive soak (10 mM, 4 days, RT) of BtMan2A 
crystals with compound 2. Surprisingly, the resulting electron density 
map showed similar diffusion of electron density and rearrangement 
of the active site, with the ligand observed further displaced from the 
expected GEI in a highly unusual 1C4-like ring conformation 
(supplemental figure 2B). We thus conclude that there exists a more 
fundamental instability in the GEI structure of BtMan2A, possibly 
explaining earlier failures to trap it. 
Soaking BsGH164 crystals with 1 or 2 (1 mM, 3 days, RT, pH 
6.5) resulted in the formation of clear covalent adducts (Figure 
2B). Both complexes have the ligand in the same position, sharing a 
4C1/E5 conformation as observed for the complex with 2FMan 
(supplemental figure 4).5 H260 shows a slight displacement in the 
complex with compound 2. We attribute this to Coulomb repulsion 
with the aziridine nitrogen, possibly explaining the weaker affinity of 
the aziridine with the BsGH164 active site in spite of an expected 
higher electrophilicity. The structure presents no obvious basis for 
the lack of reactivity with compound 3 as the pocket is quite open 
around the aziridine nitrogen. In fact, an ethylene glycol monomer is 
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observed bound where the linker could reasonably be 
accommodated.
Figure 2. A) Structure of CmMan5A labelled with compound 3. The catalytic nucleophile and general acid/base are shown in teal, other active 
site residues (and the bound acetate, ACT) are shown in white, and compound 3 is shown in green. 2Fo-Fc electron density, contoured to 
1.5σ, is shown around compound 3 and the catalytic residues. Apparent hydrogen bonding interactions are shown as black dashed lines while 
apparent hydrophobic close contacts are shown as orange dashed lines. B) Structure of BsGH164 following labelling with compound 1. The 
catalytic nucleophile, general acid/base, ligand, interactions, and electron density are shown as in panel A. Other active site residues are 
shown in light orange.
With the knowledge that GH2 and GH5 exo--mannosidases 
can be inhibited with compound 3, we sought to assess the potential 
of this molecular architecture for activity-based protein profiling 
(ABPP). ABPs 4, 5, and 6 were prepared and applied to the detection 
of MANBA in mouse kidney tissue, where MANBA is known to be 
highly expressed38, or in human plasma, where low levels of detected 
MANBA activity can be used to rule out a diagnosis of -
mannosidosis. ABPP, via in-gel fluorescence following SDS-PAGE 
separation, of diluted and pH-adjusted plasma from a healthy donor 
(measured MANBA activity = 0.07 +/- 0.002 mU/mL against 4MU-β-
Man at pH 5.5, 22°C) showed no evidence for a band at ~100 kDa, 
where MANBA is expected to appear (supplemental figure 6). The 
only apparent band ran at ¬53 kDa and reacted preferentially with 
JJB376 (a β-glucosidase probe25). In contrast, mouse kidney extracts 
treated with Cy5+-labelled ABP 4 yielded one major band at ~100 kDa 
(Figure 3A-C), consistent with MANBA. Treatment at various 
concentrations, with different incubation times and pH conditions 
demonstrated detectable labelling above background with 1 μM 
probe after 10 minutes at pH values between 4.5 and 6.0.
To confirm the identity of the labelled enzyme, mouse kidney 
protein extract was treated with DMSO control or 3 μM biotinylated 
ABP 6 with or without pre-incubation with 5 μM Bodipy-FL-ABP 5 for 
one hour. Pull-down of biotinylated proteins followed by on-bead 
trypsinolysis and LC-MS/MS analysis of the resulting peptides 
identified MANBA as the only detected glycosidase, with fewer 
peptides detected following pre-incubation with BODIPY-FL-ABP 5 
(Figure 3D). Confirmation of reactivity with MANBA shows that ABP 
4 reacts selectively and suggests that reactivity with mouse MANBA 
is relatively strong. It remains to be seen whether this relatively 
strong reactivity of mouse MANBA with 4 and 5 can be extended to 
other species, though our results with human plasma do not support 
the hypothesis that this reactivity extends to human MANBA. 
Consistent with our results with BtMan2A, competitive ABPP 
(cABPP) in mouse kidney extracts revealed no apparent inhibition of 
MANBA by 1 or 2 at 50 μM following two hours of incubation at 37°C, 
as did cABPP with cyclophellitol or click-labelled 6-deoxy-6-azido 
cyclophellitol MDW94139. However, JJB75, a potent N-alkyl aziridine 
inhibitor of β-glucocerebrosidase (GBA)26, proved to be a competitor 
for the active site of MANBA at 3 μM, suggesting that, similar to 
BtMan2A, MANBA reactivity is significantly driven by affinity for the 
N-alkyl linker.
To further test the specificity of probe 4, lysates prepared from 
HEK293T cells overexpressing non-lysosomal glucocerebrosidase 
(GBA2) were stained with Cy5-ABP (4) (Figure 3F), revealing apparent 
reactivity (qualitatively similar to previously reported labelling with 
JJB7526) with both GBA and GBA2, giving detectable labelling with 1 
μM compound 4. Competitive ABPP with 1 μM of either 
cyclophellitol or JJB75 supported the assignment of these bands as 
GBA and GBA2 since JJB75 and cyclophellitol are known to be 
efficient inhibitors of GBA and GBA2. Together, these results indicate 
that the selectivity of an assay for MANBA in mammalian tissue using 
probe 4 can be enhanced through pre-incubation of the sample with 
cyclophellitol to eliminate interference from GBA and GBA2 without 
reducing signal from MANBA.
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Figure 3. A-C) Concentration-, time-, and pH-dependence (see supplemental information for full incubation conditions) of MANBA labelling 
with ABP 4 in mouse kidney extracts. D) Pulldown proteomic detection of MANBA from mouse kidney extracts. E) cABPP of MANBA in mouse 
kidney extracts. SDS indicates denaturation with 2% (w/v) SDS prior to labelling, CP indicated cyclophellitol, MDW94139 and JJB7526 are 
established probes for GBA, M indicates molecular weight ladder. F) cABPP of GBA and GBA2 in HEK293 cells. Labels are the same as in E.
Conclusions
We have demonstrated that, as has been previously shown for 
other retaining glycosidases, exo--mannosidases can be inhibited 
covalently and irreversibly with appropriately configured 
cyclophellitol analogues, particularly those designed with N-alkyl 
aziridine warheads. Our structural work shows that the epoxide and 
aziridine inhibitors bind BsGH164 in the same conformation found as 
2FMan and that the N-alkyl aziridine binds to CmMan5A in the 
expected OS2-like conformation of the GH5 exo-β-mannosidase GEI. 
While exhibiting low potencies, the inhibitors and ABPs presented 
here react irreversibly with the catalytic nucleophile, displaying 
sufficient stability and specificity to enable near-quantitative 
labelling of the catalytic nucleophile. In spite of their limited 
reactivity, tagged N-alkyl aziridine derivatives were moreover 
successfully applied to ABPP in both chemical proteomics and in-gel 
fluorescence formats, as shown by detection, enrichment, and 
identification of MANBA from mouse kidney extracts.
Experimental details
Materials and instrumentation
All chemicals were purchased from Sigma Aldrich unless otherwise 
specified. β-d-mannopyranose-configured cyclophellitol was synthesized as 
described in the supplemental synthetic methods and compound 
characterization section.
Recombinant enzyme production
Bs164 was expressed and purified as in Armstrong and Davies.5 Briefly, a 1 
ml starter culture of pET28-His6-Bs164 in BL21(DE3) gold cells was used to 
inoculate NZYTech autoinduction media (NZYTech) containing 50 μg/ml of 
kanamycin. Expression cultures were grown at 37°C with shaking at 250 
rpm for 6 h, the temperature was then decreased to 20°C and cultures were 
incubated for an additional 22 h. Expression cultures were harvested by 
centrifugation (5,000 × g, 30 min, 4°C) and cell pellets were stored at −70°C 
until purification. Cell pellets were resuspended in 120 ml of 50 mM HEPES, 
30 mM imidazole, 200 mM NaCl, pH 7.4 with additional protease inhibitor 
(4-(2-aminoethyl)benzenesulfonyl fluoride, 0.1 mM) lysozyme, and DNase. 
Resuspended cells were then lysed by passage through a cell-disruptor 
homogenizer at 25 kpsi. Cell lysate was clarified by centrifugation (18,000 × 
g, 30 min, 4°C) then loaded directly onto a 5-ml His-tag Excel column (GE 
Healthcare). Bound protein was eluted with a linear gradient of 0–100% 50 
mM HEPES, pH 7.4, 1 M imidazole, 200 mM NaCl) over 20 column volumes, 
concentrated with a 30-kDa cut-off Amicon centrifugal filter unit, and further 
purified by gel filtration (HiLoad 16/600 Superdex 200 pg; GE Healthcare) in 
50 mM HEPES, 200 mM NaCl, pH 7.4. The purity of eluted protein was 
analyzed by SDS-PAGE and protein-bearing fractions were pooled and 
concentrated with a 30-kDa cutoff Amicon centrifugal filter unit. 
Concentrated protein was diluted with 20 mM HEPES, pH 7.4, concentrated 
again, then diluted to 30 mg/ml with the same buffer and flash frozen with 
liquid nitrogen until use. Protein concentrations were determined 
spectrophotometrically using a calculated ε280 of 128,480 M−1 cm−1.
CmMan5A2 was codon optimized for E. coli, synthesized and cloned into 
pET24a between the NdeI and XhoI restriction sites by Genscript 
(Netherlands) to add a C-terminal 6xHis tag, matching the previously 
crystallized form. The plasmid was transformed into BL21(DE3) gold cells 
and expressed in ZYM-5052 autoinduction medium40 with 50 μg/ml of 
kanamycin, 2 mM MgSO4 and no added micronutrients for 20 hours at 30°C 
(starting OD600 = 0.03). Collected cells were resuspended in 0.05 volumes 
of 50 mM NaPi, 300 mM NaCl, 20 mM imidazole, pH 7.5 supplemented with 
0.1 mg/mL lysozyme and were lysed by sonication on ice for 5 minutes with 
40% amplitude and 30% duty cycle. Lysate was clarified by centrifugation at 
18,000 × g for 10 min at 4°C, then loaded onto a 5 mL Histrap crude FF 
column (GE Healthcare). Protein was washed with 10 CV of binding buffer 
then eluted with a gradient from 20-500 mM imidazole. Protein-bearing 
fractions were concentrated using a 10 kDa MWCO Amicon centrifugal 
concentrator, then purified over Superdex 200 into 20 mM Na-MOPS pH 7.0. 
The heart-cut of the major elution peak was pooled and concentrated to ~50 
mg/mL using a 10 kDa MWCO Amicon centrifugal concentrator, and frozen 
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at -70°C. Protein was quantified spectrophotometrically using a calculated 
ε280 of 120780 M-1cm-1. 
The gene encoding BtMan2A was expressed, and BtMan2A was purified 
using similar methods to Tailford et al.4 Briefly, an 8 ml starter culture of 
pET28a-BtMan2A-His6 was used to inoculate 800 mL Luria Broth with 50 
ug/ml of kanamycin. Expression cultures were grown at 37°C with shaking 
at 180 rpm for about 3 hours until an OD 600 of 0.7 was reached. Isopropyl 
β- d-1-thiogalactopyranoside was added to 1 mM, and the temperature 
was then decreased to 16°C and the culture incubated for an additional 21 
h. The expression culture was harvested by centrifugation (5,000 × g, 30 
min, 4°C) and the cell pellet was stored at −70°C until purification. The cell 
pellet was resuspended in 40 ml of binding buffer, comprised of 50 mM 
HEPES, 10 mM imidazole, 0.5 M NaCl, 10 mM β-mercaptoethanol pH 
8.0, with additional protease inhibitor (4-(2-aminoethyl)benzenesulfonyl 
fluoride, 1 mM) and 1 cOmplete™ Protease Inhibitor Cocktail tablet (Roche). 
Cells were lysed by sonication, the lysate was clarified by centrifugation at 
15,000 × g for 30 min at 4°C, and the supernatant was filtered through a 
0.22 μM syringe filter and loaded onto a 1 mL HisTrap FF column (GE 
Healthcare). The protein was washed with 20 CV of binding buffer, then 
eluted with a gradient into buffer with 500 mM imidazole over 20 CV. Protein-
bearing fractions were concentrated using a 30 kDa MWCO Vivaspin 
centrifugal concentrator, then purified over Superdex 200 into 50 mM 
HEPES pH 8.0, 150 mM NaCl, 2 mM DTT. The major elution peak fractions 
were pooled and buffer-exchanged into 50 mM HEPES pH 8.0, 2 mM DTT, 
and then loaded onto a 1 ml HiTrap Q column, equilibrated with the same 
buffer. The protein was eluted using a gradient into loading buffer with 0.5 
M NaCl over 20 CV. The main peak fractions were buffer-exchanged into 10 
mM HEPES pH 8.1, 5 mM TCEP, concentrated to 15 mg/ml and flash frozen 
with liquid nitrogen until use. Protein concentrations were determined 
spectrophotometrically using a calculated ε280 of 183,955 M −1 cm −1.
Enzyme labelling detected by intact mass spectrometry and 
activity measurement
Bs164 and BtMan2A were diluted to 0.2 mg/mL in assay buffer 1 (80 mM 
Na-MES pH 5.5, 160 mM NaCl). CmMan5A was diluted in assay buffer 2 
(20 mM Na-MOPS pH 7.5). Inhibitors 1, 2 or 3 (10 mM, 1 μL), or 1 uL of 
water were mixed with 9 μL of each enzyme stock and the reactions were 
incubated at 30°C with a heated lid to prevent evaporation. A 2 μL sample 
taken after 25 hours was diluted with 8 μL of 1% formic acid, 10% acetonitrile 
and analyzed as described previously.20 A separate 2 uL sample was taken 
at the same time and diluted with 23 uL of assay buffer 1 (Bs164), 398 uL of 
assay buffer 1 (BtMan2A) or 23 uL of assay buffer 2 (CmMan5A). To each 
of these in a single well of a black plastic 384-well plate was added 25 uL of 
0.2 mM 4-Methylumbelliferyl β-D-mannopyranoside (Sigma) in water. 
Fluorescence was monitored continuously over 15 minutes via excitation at 
360 nm and emission monitoring at 450 nm using a Clariostar (BMG 
Labtech) plate reader with temperature control set to 25°C. Fluorescence 
over time measurements were converted into rates using a 4MU calibration 
series in each assay buffer and divided by the measured un-inhibited control 
reaction rate to obtain residual activity.
Enzyme crystallization
Crystals of Bs164 were grown in MRC maxi 48-well-plates using the sitting-
drop vapor-diffusion method at 20°C. The protein solution contained His6-
Bs164 at 30 mg/ml in 20 mM HEPES pH 7.4 buffer. Well solution contained 
100 mM ammonium tartrate dibasic (pH 7.0) and 13% (w/v) PEG 3,350 and 
the protein:well solution ratio was 500:500 nl. To obtain an inhibitor-enzyme 
complex structure the inhibitor (1 mM final concentration) was added to the 
crystallization drop and incubated for 3 days. The crystals were 
subsequently cryo-protected in well solution containing 25 % ethylene glycol 
and flash cooled in liquid nitrogen.
Crystals of CmMan5A were initially grown from 30 mg/mL protein as 
described previously.2 A seed stock was prepared from needle clusters 
using the seed bead kit (Hampton research). CmMan5A labelled with 
compound 3 was prepared by mixing 20 uL of 50 mg/mL enzyme with 5 uL 
of 10 mM compound 3 in 10% DMSO and incubating this for 25 hours at 
30°C. 100 nL of this was sampled and diluted into 10 uL of 1% formic acid, 
10% acetonitrile and analyzed as above to assess the degree of labelling. 
Crystals of CmMan5A labelled with compound 3 were grown in maxi 48-
well-plates using the sitting-drop vapor-diffusion method at 20°C by mixing 
100 nL of seed stock into 600 nL of well solution, then adding 900 nL of 
protein solution. Crystals were apparent after overnight incubation but were 
allowed to continue growing for 3 days prior to freezing without cryo-
protection. 
BtMan2A was crystallized in MRC maxi 48-well-plates using the sitting-drop 
vapour-diffusion method at 20°C. The drop comprised 0.65 μl protein (at 10 
mg ml-1 in 10 mM HEPES pH 8.1, 5 mM TCEP) and 0.35 μl mother liquor 
consisting of 14 % (w/v) PEG 3350, 0.2 M sodium bromide, 0.1 M MES (2-
(N-morpholino) ethanesulfonic acid) pH 6.7, for the crystal soaked with 2. 
The drop comprised 1.2 ul protein (at 7.5 mg ml-1 in 10 mM HEPES pH 8.1, 
2.5 mM TCEP) and 1.2 ul mother liquor consisting of 12 % (w/v) PEG 3350, 
0.2 M sodium bromide, 0.1 M MES pH 5.5, for the crystal soaked with 3. The 
crystal soaks were performed with 10 mM 2 for 4 days, and with 1 mM 3, 1% 
(v/v) DMSO, for 3 days, and the crystals were fished into liquid nitrogen 
using a nylon CryoLoop (Hampton Research) via a cryoprotectant consisting 
of the mother liquor components with 25 % ethylene glycol.
Diffraction, structure solution, and refinement
All diffraction data were collected using a wavelength of 0.9763 Å. Diffraction 
data for BtMan2A soaked with compounds 2 and 3 were collected at 100 K 
out to 2.05 and 1.85 Å, on beamlines I04-1 and I03, respectively. The data 
were processed using the Xia241 pipeline with Dials42. Diffraction data for 
CmMan5A in complex with compound 3 were collected out to 1.30 Å at 100 
K on beamline I03 at Diamond Light Source (Harwell) and processed using 
the Xia2 pipeline with XDS43. Diffraction data for Bs164 soaked with 
compounds 1 and 2 were collected out to 1.75 Å and 2.05 Å at 100 K on 
beamline I03 at Diamond Light Source (Harwell) and processed using the 
Xia2 pipeline with Dials (See supplemental table 1 for X-ray data collection 
and refinement statistics). Structures were solved by molecular replacement 
using Phaser44 or Molrep45 with the known unliganded enzyme structures 
(PDBID: 2JE8 (BtMan2A), 1UUQ (CmMan5A), 6T5O (Bs164)) as search 
models. The resulting solutions showed difference density for the bound 
ligands within the enzyme active sites. Ligand coordinates and dictionaries 
were generated using AceDRG46 or jLigand47 and built into the model using 
Coot48, followed by alternating rounds of manual model building and density 
refinement using Coot and REFMAC49 within the CCP4 suite50. Models were 
validated using MolProbity51 and the wwPDB OneDep validation server. 
Activity assay and ABPP of human plasma
5 mL of blood was collected from a healthy volunteer into an EDTA-
containing collection tube. Cells were removed by centrifugation and plasma 
was aspirated gently. 450 μL of plasma was pH-adjusted with 50 μL of 500 
mM pH 5.5 sodium citrate buffer. 50 μL of the buffered plasma was then 
diluted with 950 μL of ultrapure water. A negative control sample was 
prepared by supplementing diluted plasma with 0.05 volumes of 10% SDS 
and heating to 95°C for 5 minutes. An additional 0.05 volumes of water was 
added to the diluted plasma for equivalence.
For activity measurements, 20 μL of each sample was mixed with 20 μL of 
200 μM 4MU-β-mannoside (Sigma) in a 384-well plate and incubated at 
22°C for 30 minutes. 10 μL of 1 M Na2CO3 was then added and F360/450 
was measured using a Clariostar plate reader (BMG Labtech). Free [4MU] 
was quantified against a calibration series prepared in 200 mM Na2CO3. 
For ABPP, buffered and diluted plasma samples were supplemented with 
probe to a final concentration of 3 μM and incubated at 37°C for 2 hours. 10 
μL (~4 μg total protein) was separated by SDS-PAGE and the resulting gel 
was imaged for fluorescence using a Typhoon 5 laser scanner (GE 
Healthcare).
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Fluorescence ABPP of mouse kidney extract
Kidneys from wild type mice were homogenized in KPi buffer (25 mM 
K2HO4/KH2PO4, 0.1% (v/v) Triton X-100, protease inhibitor cocktail (Roche, 
EDTA-free)) with 1mm glass beads and a FastPrep- 24 homogenizer (MP 
Biomedicals). The basic labeling condition consists of equilibrating 25 μg 
total protein from the homogenate in McIlvaine buffer (150 mM, various pH) 
in a total volume of 10 μL, and ABP labeling with 5 μL of 3x concentrated 
ABP prepared in McIlvaine buffer. For concentration dependent labeling, 
mouse tissue homogenates were equilibrated in McIlvaine buffer pH 5.5 for 
15 min at 37 °C, followed by incubation with various probe concentrations 
up to 10 μM 4 (end concentration, pH 5.5) at 37 °C for 1 h. For labeling at 
varying pH, mouse tissue homogenates were equilibrated in McIlvaine buffer 
pH 4.0 – 7.0 for 15 min at 37 °C, followed by incubating with 1 μM 4 
(prepared in McIlvaine buffer pH 4.0 -7.0) for 1 h at 37 °C. For labeling at 
varying incubation time, mouse kidney homogenates were prepared as 
above, and incubated with 1 μM 4 (end concentration; pH 5.5) at 37 °C for 
2 min to 2 h. For cABPP, mouse tissue homogenates were pre-incubated 
with either SDS (2 % (w/v)), cyclophellitol (3 μM), ABP MDW941 (3 μM), 
ABP JJB75 (3 μM), 1-3 (50 μM), 5 (3 μM), or 6 (50 μM) at 37 °C for 2 h, 
followed by incubation with 4 (3 μM) at 37 °C for 2 h. After incubation, 
samples were denatured with 3.75 μL 5X Laemmli’s sample buffer at 98 °C 
for 5 min, resolved in 7.5% SDS-PAGE gels, and wet slab gels were 
scanned for Cy5+ fluorescence by a Typhoon FLA 9500 imager (GE 
Healthcare). Coomassie stain were carried out to confirm equal loading.
Pull-down and LC/MS analysis with ABP 6
4.0 mg total protein from mouse kidney homogenates were incubated with 
either DMSO, 10 μM biotin probe 6, or 5 μM Bodipy-FL probe 5 followed by 
10 μM 6, each step being incubated for 1 h at 37 °C in a total volume of 500 
μL McIlvaine buffer pH 5.5 (75 mM citric acid/Na2HPO4). Samples were 
subsequently denatured with the addition of 125 μL 10% (w/v) SDS and 
boiling for 5 min at 100°C. From here on, samples were prepared for pull-
down with streptavidin beads as published earlier.52 After the pull-down 
procedure, half of the samples were treated by the trypsin digestion buffer 
(100 mM Tris-HCl pH 7.8, 100 mM NaCl, 1 mM CaCl2, 2% (v/v) acetonitrile 
(ACN) and 10 ng/μL trypsin) and the bead suspension was incubated in a 
thermoshaker at 37 °C overnight. The supernatant containing the trypsin-
digested peptides was desalted using stage tips, followed by evaporation 
and redissolving in 75 μL sample solution (H2O/ACN/formic acid, 95/3/0.1, 
v/v/v). The beads containing active-site peptides were eluted with elution 
buffer (5% (v/v) formic acid, 25% (v/v) ACN, 70% (v/v) H2O, 10 μM biotin) 
for 30 min at 37 °C, after which the supernatant was desalted using stage 
tips and prepared for LC/MS analysis using the abovementioned procedures. 
For the LC/MS analysis, 1 μL of sample was injected with phase A (0.1 % 
(v/v) formic acid in ultrapure H2O) on a C18 column (Acquity UPLC M-Class 
300 μm x 50 mm, packed with BEH C18 material of 1.7 μm diameter and 
300 Å pore size particles), eluted with a 50 min gradient of 10% to 60% 
phase B (0.1 % (v/v) formic acid in ACN), followed by 10 min equilibration to 
1% phase B at a flow of 0.4 μL/min, hyphenated with Electro-spray ionization 
(ESI) via Nano-spray source with ESI emitters (New Objectives) fused silica 
tubing 360 μm OD x 25 μm ID tapered to 5 ± 0.5 μm (5 nL/cm void volume) 
to a Synapt G2Si mass spectrometer (Waters) operating with Masslynx for 
acquisition and Ent3 software for polymer envelope signal deconvolution. 
The following settings in positive resolution mode were used: source 
temperature of 80°C, capillary voltage 4.5 kV, nano flow gas of 0.25 Bar, 
purge gas 250 L/h, trap gas flow 2.0 mL/min, cone gas 100 L/h, sampling 
cone 25V, source offset 25, trap CE 32V, scan time 3.0 sec, mass range 
400-2400 m/z. Lock mass acquiring was done with a mixture of Leu Enk 
(556.2771) and Glu Fib (785.84265), lockspray voltage 3.5 kV, Glufib 
fragmentation was used as calibrant. The PLGS (Waters) program was used 
for data analysis, protein ID or extraction of mgf files for further Mascot 
(Matrix Science) search analysis.
ABPP of HEK293T cells overexpressing GBA2
HEK293T cells were purchased from ATCC and handled according to the 
published methods.53 18.9 µg of lysates from GBA2-overexpressing 
HEK293T cells54 were pre-incubated with 1 µM of JJB75 compound 1, 3, 5, 
6, or 2% (w/v) SDS (with 5 min boiling at 98ºC when pre-incubation was 
completed) at pH 5.5 for 1 h at 37 ºC, and next incubated with 1 μM ABP 4 
at pH 5.5 for 2 h at 37 ºC. Samples were denatured and subjected to SDS-
PAGE and fluorescence detection. The gel was stained with Coomassie 
Brilliant Blue G250 to confirm equal protein loading.
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